MEDS Stock Alert: DataMEDS AI Parabolic Squeeze Trade

DataMeds AI Inc. (NASDAQ: MEDS) delivered a textbook parabolic short squeeze on Wednesday, September 16, 2026, exploding from an open of $4.04 to an intraday high of $12.31 before closing at $6.07 on massive volume.

On September 15, 2026, DataMEDS announced the completed acquisition of Helomics Corporation (a precision oncology platform applying AI to real-world tumor data for drug discovery and cancer treatment decisions. The deal structure was striking for $1.5million in shares and an acquisition note, the company received a certified clinical laboratory, Predictive Oncology’s contract research business, and $1.5 million in cash back (essentially making is a no net cost acquisition of functioning oncology infrastructure).

The Helomics acquisition provided MEDS a credible story in two of the most speculative sectors in a small-cap trading simultaneously (AI healthcare and oncology data). The narrative of a small-cap AI company pivoting into oncology diagnostics and cancer screening was exactly what retail momentum traders are looking for.

The intraday range from $4.04 to $12.21 reflects just how violent the supply and demand imbalance became once the volume flooded in.

Our scanner flagged MEDS early in the session. We waited for the right setup to confirm before acting, then entered and alerted the Atlantic Trading community. This trade was entered and exited on September 16, 2026.